US Pharma MarketingRemix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader
Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR…
A nimble biotech working on small molecule mRNA degraders will take the Nasdaq listing of a once-promising gene therapy biotech co-founded by Jim Wilson.
Remix Therapeutics plans to take over Passage Bio's ...
Source: Endpoints News